New potential selective estrogen receptor modulators in traditional Chinese medicine for treating menopausal syndrome

被引:0
作者
Song, Xintong [1 ]
Shen, Lan [1 ]
Contreras, Janine Micahella [2 ]
Liu, Zhiyuan [1 ]
Ma, Kai [1 ]
Ma, Biao [3 ]
Liu, Xiaoling [1 ]
Wang, Dan Ohtan [1 ,2 ]
机构
[1] Shenyang Pharmaceut Univ, Wuya Coll Innovat, Shenyang 110016, Peoples R China
[2] New York Univ Abu Dhabi, Biol Program, Abu Dhabi, U Arab Emirates
[3] RIKEN Ctr Computat Sci, Kobe, Japan
基金
中国国家自然科学基金;
关键词
estrogen receptor; menopausal syndrome; SERM; traditional Chinese medicine; women; HORMONE REPLACEMENT THERAPY; INVASIVE BREAST-CANCER; FACTOR-KAPPA-B; POSTMENOPAUSAL WOMEN; OVARIECTOMIZED RATS; GINSENOSIDE RG1; BONE LOSS; IN-VITRO; ANTIOSTEOPOROTIC ACTIVITY; GENITOURINARY SYNDROME;
D O I
10.1002/ptr.8289
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Women go through several predictable conditions and symptoms during menopause that are caused by age, changes in sex hormone levels, and other factors. Conventional menopause hormone therapy has raised serious concerns about the increased risks of cancers, blood clots, depression, etc. Selective estrogen receptor modulators (SERMs) that can be both agonists and antagonists of estrogen receptors in a tissue-specific manner are being developed to reduce the health concerns associated with menopause hormone therapy. Here, we have searched the Chinese national traditional Chinese medicine (TCM) patent database to identify potential SERM-like compounds with reduced health risks. TCM has been widely used for treating complex symptoms associated with menopause syndrome and thus can be a particularly rich source for pharmaceutical alternatives with SERM properties. After extensive literature review and molecular simulation, we conclude that protopanaxatriol, paeoniflorin, astragalin, catalpol, and hyperoside among others may be particularly promising as SERM-like compounds in treating the menopausal syndrome. Compounds in TCM hold promise in yielding comparable outcomes to hormone therapy but with reduced associated risks, thus presenting promising avenues for their clinical applications.
引用
收藏
页码:4736 / 4756
页数:21
相关论文
共 190 条
[31]   Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Clinical Practice Guideline [J].
Eastell, Richard ;
Rosen, Clifford J. ;
Black, Dennis M. ;
Cheung, Angela M. ;
Murad, M. Hassan ;
Shoback, Dolores .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2019, 104 (05) :1595-1622
[32]   The effects of alone and combination tamoxifen, raloxifene and estrogen on lipid profile and atherogenic index of ovariectomized type 2 diabetic rats [J].
Ebrahimi, Mohammad Navid ;
Khaksari, Mohammad ;
Sepehri, Gholamreza ;
Karam, Gholamreza Asadi ;
Raji-amirhasani, Alireza ;
Azizian, Hossein .
LIFE SCIENCES, 2020, 263
[33]   Lasofoxifene and Cardiovascular Events in Postmenopausal Women With Osteoporosis Five-Year Results From the Postmenopausal Evaluation and Risk Reduction With Lasofoxifene (PEARL) Trial [J].
Ensrud, Kristine ;
LaCroix, Andrea ;
Thompson, John R. ;
Thompson, David D. ;
Eastell, Richard ;
Reid, David M. ;
Vukicevic, Slobodan ;
Cauley, Jane ;
Barrett-Connor, Elizabeth ;
Armstrong, Roisin ;
Welty, Francine ;
Cummings, Steven .
CIRCULATION, 2010, 122 (17) :1716-+
[34]   Catalpol coordinately regulates phase I and II detoxification enzymes of Triptolide through CAR and NRF2 pathways to reduce Triptolide-induced hepatotoxicity [J].
Fu, Ling ;
Zhou, Lingling ;
Geng, Shan ;
Li, Ming ;
Lu, Wei ;
Lu, Yan ;
Feng, Zhe ;
Zhou, Xueping .
BIOMEDICINE & PHARMACOTHERAPY, 2020, 129
[35]  
Gabriel EM, 2012, EXPERT REV ANTICANC, V12, P223, DOI [10.1586/ERA.11.206, 10.1586/era.11.206]
[36]  
Gambacciani M, 2014, PANMINERVA MED, V56, P115
[37]   Ginsenoside Rg1 activates ligand-independent estrogenic effects via rapid estrogen receptor signaling pathway [J].
Gao, Quan-Gui ;
Zhou, Li-Ping ;
Lee, Vien Hoi-Yi ;
Chan, Hoi-Yi ;
Man, Cornelia Wing-Yin ;
Wong, Man-Sau .
JOURNAL OF GINSENG RESEARCH, 2019, 43 (04) :527-538
[38]   Differential ERα-mediated rapid estrogenic actions of ginsenoside Rg1 and estren in human breast cancer MCF-7 cells [J].
Gao, Quan-Gui ;
Chan, Hoi-Yi ;
Man, Cornelia Wing-Yin ;
Wong, Man-Sau .
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2014, 141 :104-112
[39]  
Gharehbagni M, 2010, CLIN EXP OBSTET GYN, V37, P112
[40]   Ospemifene 12-month safety and efficacy in postmenopausal women with vulvar and vaginal atrophy [J].
Goldstein, S. R. ;
Bachmann, G. A. ;
Koninckx, P. R. ;
Lin, V. H. ;
Portman, D. J. ;
Ylikorkala, O. .
CLIMACTERIC, 2014, 17 (02) :173-182